SOURCE: Goldman Small Cap Research, Inc.

August 08, 2013 09:02 ET

Nuvilex Is the Rodney Dangerfield of Biotechs

BALTIMORE, MD--(Marketwired - Aug 8, 2013) - In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that Nuvilex Inc. (OTCQB: NVLX) trades and is valued like a biotech version of the late, great comedian Rodney Dangerfield, who was famous for his "I Get No Respect" mantra.

Moreover, Goldman Small Cap Research believes that is all about to change and predicts that Nuvilex will ultimately turn from Rodney Dangerfield into Cinderella.

As an example, Goldman refers to the surprising trading and valuation of one of Nuvilex's sister biotech stocks this quarter. The exciting and very promising company, Inovio Pharmaceuticals, Inc., recently reached a peak rise in price of nearly 300% in the past 3 weeks.

Analyst Rob Goldman notes, "While the magnitude of the rise has baffled some market watchers, one of the major drivers was news that in preclinical animal models, Inovio demonstrated that its vaccine showed the potential to reduce tumors and prevent tumor recurrence by a wide margin versus the peer technology."

"Nonetheless, if success in an animal model cancer study and a vaccine in Phase II clinical trials are worth a peak market cap of over $500M, Goldman posits that the $70M in market cap Nuvilex should be worth at least half that much considering it is further along the development path."

After a series of fits and starts, Nuvilex now owns exclusive rights to a live-cell encapsulation platform technology for all cancers and that has not only successfully completed Phase II trials for advanced, inoperable pancreatic cancer, but comprehensive animal trials for mammary (breast) cancer, and is on the verge of acquiring similar rights to the technology to fight diabetes. Moreover, management is gearing up for next stage of trials for pancreatic cancer due to its outstanding Phase II trial results.

In the article, Goldman suggests that if the Company had gone through these steps in quicker fashion or its stock was uplisted, its market cap would be at a similar level to that of Inovio. Still, Inovio has been around for 30 years, so it has taken them quite some time to get to this point, despite its amazing rise in 6 weeks.

As institutional and retail investors scour the health care family for under-the-radar stocks trading at major discounts to their peer group despite being further along in the development process, Goldman deems it is likely that Nuvilex will begin to get the respect it is due and investors will be rewarded.

To view Nuvilex reports and articles or to download the report in its entirety, please visit

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. For more information, visit

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: 

Contact Information